Back to Search
Start Over
Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B
- Source :
- Clinical and Molecular Hepatology, Vol 27, Iss 2, Pp 295-304 (2021)
- Publication Year :
- 2021
- Publisher :
- Korean Association for the Study of the Liver, 2021.
-
Abstract
- Background/Aims The immune-tolerant (IT) phase of chronic hepatitis B (CHB) patients is not generally indicative of antiviral therapy (AVT). We assessed and compared the risk of hepatocellular carcinoma (HCC) during the IT-phase stringently defined by a low fibrosis-4 (FIB-4) index, compared to that in patients undergoing AVT. Methods Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B virus-DNA >20,000 IU/mL, with normal alanine aminotransferase level from 2012 to 2018, those with a FIB-4 index of
Details
- Language :
- English
- ISSN :
- 22872728 and 2287285X
- Volume :
- 27
- Issue :
- 2
- Database :
- Directory of Open Access Journals
- Journal :
- Clinical and Molecular Hepatology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.70109bee11ff4d72ac16291bcdbd3083
- Document Type :
- article
- Full Text :
- https://doi.org/10.3350/cmh.2020.0216